# A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer

> **NCT03425565** · PHASE2 · UNKNOWN · sponsor: **University College, London** · enrollment: 48 (actual)

## Conditions studied

- Clear Cell Tumor
- Gynecologic Cancer
- Advanced Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03425565
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-18
- **Primary completion:** 2024-09
- **Final completion:** 2024-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03425565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03425565, "A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03425565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*